Cellmid is an Australian life sciences company listed on the Australian Stock Exchange (ASX: CDY). Cellmid’s overarching mission is to help people live longer, in good health and with confidence; retaining vitality and without the side effects commonly associated with aging.
With a focus on developing innovative solutions to conditions associated with aging Cellmid applies the same scientific rigor in its development programs irrespective of whether they are for consumer products or pharmaceuticals.
The Company, through its wholly owned subsidiaries Lyramid, and Advangen, develops innovative novel therapies, treatments and diagnostic tests, leveraging an extensive intellectual property portfolio relating to the novel targets midkine (MK) and FGF5. Cellmid’s consumer health products are marketed through a global network of retailers and wholesalers, in addition to a direct-to-consumer e-commerce platform.
Through its wholly owned subsidiary Advangen, Cellmid develops, manufactures and markets anti-aging products globally, with its FGF5 inhibitor hair health and hair growth products sold worldwide. The flagship anti-aging hair care range, marketed as evolis®, Advangen® Jo-Ju® and Lexilis® brands, is sold in channels including QVC Japan, premium retailer Nieman Marcus and Bloomingdales in the USA, Douglas Perfumery in Europe and in Priceline and other pharmacies and beauty retailers in Australia. Advangen is rapidly expanding in other territories with distribution agreements signed in China and Korea. Advangen continues to grow its product portfolio through dedicated research and development, concurrently to rapidly scaling into its global distribution network. For further information visit www.evolisproducts.com.au.
Lyramid, Cellmid’s wholly owned subsidiary, controls the largest suite of intellectual property around the novel protein target midkine globally, with patents including composition of matter and methods of use of recombinant midkine protein and anti-midkine antibodies and other anti-midkine therapies. Lyramid develops innovative drugs against diseases caused by “inflamm-aging”; the inflammatory processes that contribute to aging and age-related diseases. For that purpose, Lyramid focusses on blocking midkine, a protein that plays an important role in autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer and neurodegenerative diseases. For more information visit www.Lyramid.com.au